Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 386

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 386
---
 
    30,435
  
    Paul Lytle 
     
    12/16/2020(1)
     
    –
     
    –
     
    –
     
    –
     
    42,392
     
    29,674

    12/16/2020(2)
     
    –
     
    –
     
    –
     
    –
     
    37,772
     
    26,440

____________________

(1)RSU award will vest 100% on the sooner of (i) August 31, 2026, provided the Company is listed on a national
exchange such as the Nasdaq Stock Market prior to August 31, 2026 (ii) upon a merger or acquisition of the Company, provided the holder
agrees to accept the underlying shares in writing, or (iii) upon the holders last date of employment, provided the holder agrees to accept
the underlying shares in writing.

(2)RSU award will vest 100% on the sooner of (i) August 31, 2027, provided the Company is listed on a national
exchange such as the Nasdaq Stock Market prior to August 31, 2027 (ii) upon a merger or acquisition of the Company, provided the holder
agrees to accept the underlying shares in writing, or (iii) upon the holders last date of employment, provided the holder agrees to accept
the underlying shares in writing.

(3)Market value is calculated based on the closing price of our common stock of $0.70 per share on December
31, 2024, times the number of shares subject to the RSU award. Each RSU represents the contingent right to receive, upon vesting, one
share of our common stock.

 43 

    ITEM 12.
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Share Ownership

The following table sets forth information, as of
March 31, 2025, regarding the beneficial ownership of our common stock and Series B Preferred by:

·Each person known by us to be a beneficial owner
of more than five percent (5%) of our outstanding common stock; 

·each person known by us to be a beneficial owner
of more than five percent (5%) of our Series B Preferred Stock; 

·each of our directors;

·each